Plasma drug concentrations of 4-drug fixed-dose combination regimen and its efficacy for treatment of pulmonary tuberculosis under National Tuberculosis Elimination Programme: A prospective pilot study

Bargaje, Medha; Bharaswadkar, Sandeep; Lohidasan, Sathiyanarayanan; Panda, Bijoy Kumar

doi:10.1016/j.ijtb.2021.04.002

Cited by 3 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite several advantages, such as reduced pill burden and ease of prescription and transport, there have been several issues with the use of FDC in TB treatment. Studies investigating differences in rifampicin bioavailability between FDC and single-drug formulations published in the 2000s generally suggested decreased bioavailability of rifampicin when taken as an FDC 10 11 24–26. In relatively recent studies reported in 2014, 2015 and 2018, not all FDCs were bioequivalent to the single drug reference 27–29.…”

Section: Discussionmentioning

confidence: 99%

Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data

Ki,

Jeong,

Kang

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

BackgroundThe fixed-dose combination (FDC) for first-line antituberculosis (TB) treatment has long been a standard practice worldwide; however, there is limited evidence on whether the use of FDC improves long-term treatment outcomes in the real-world setting.MethodsWe identified 32 239 newly diagnosed patients with drug-susceptible (DS) TB in 2015 and 2016 who had been prescribed FDC or non-FDC TB treatment from a multiyear (2013–2018) national TB cohort database that linked the Korean National Tuberculosis Surveillance System, the National Health Insurance Database and the Health Insurance Review and Assessment Service database. Inverse probability of treatment weighting (IPTW) with a propensity score was used to control for differences in patient characteristics between 5926 patients with TB treated with FDC and 26 313 patients with non-FDC. Multivariable logistic regression analyses were performed to assess for the factors influencing treatment outcomes between the two groups.ResultsAfter IPTW, new patients with DS-TB treated with FDC had higher treatment completion rate (83.9% vs 78.9%, p<0.01) and lower death rates (8.2% vs 9.8%, p<0.01) with similar TB recurrence rate (2.3% vs 2.4%) compared with those treated with non-FDC. In multivariable analyses, FDC use had higher odds treatment completion (adjusted OR 1.45; 95% CI 1.34 to 1.56). Patients with TB with younger age (relative to 70+ age) and higher income level had higher odds for treatment completion. Use of FDC did not influence TB recurrence after treatment completion (adjusted HR 0.94; 95% CI 0.77 to 1.16). The acquired drug resistance rate was similar between the two groups (drug-resistant TB in FDC 4.7% vs non-FDC 5.3%; p=0.80).ConclusionIn Korea, prescription of FDC to treat newly diagnosed patients with DS TB improved patient’s treatment completion. Use of FDC did not increase the risks of TB recurrence or development of drug resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data

Ki,

Jeong,

Kang

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

show abstract

“…Treatment of TB in HIV patients is the same as for HIV-negative TB patients for at least six months with a 2HRZE/4HR (category 1 regimen), but some cases take longer, about eight to twelve months (Cox et al, 2021;Jeong et al, 2022;Kumari et al, 2024). Patients with TB and HIV have a higher risk of death, treatment failure, and relapse (Bargaje et al, 2022;Fetensa et al, 2024). ART significantly improves the response to TB treatment and outcomes in individuals with…”

Section: Introductionmentioning

confidence: 99%

Factors Associated with Successful Drug Susceptible Tuberculosis Treatment among Tuberculosis – Human Immunodeficiency Virus Patients in DKI Jakarta Province 2020 – 2022

Budiyani,

Djuwita,

Mahkota

et al. 2024

AJESH

View full text Add to dashboard Cite

Tuberculosis and HIV are serious health issues that can significantly impact an individual's immune system by evading immune monitoring functions. Research on TB-HIV treatment success, especially in DKI Jakarta province, is still limited. This study aims to assess the treatment success of tuberculosis patients who also have HIV co-infection through an analysis of the patient's sociodemographic and clinical characteristics. This cross-sectional study used secondary data from the Tuberculosis Information System (SITB) of the DKI Jakarta Provincial Health Office from 2020 to 2022. We conducted a chi-square bivariate test, and for multivariate analysis, we used the Cox Regression with constant time at risk to provide Prevalence Rasio (PR). Out of 1902 patients with TB-HIV, the TB treatment outcome was successful in 73.29% (cured and completed treatment) and unsuccessful in 26.71% (failed, died, or lost to follow-up). There was a higher chance that TB treatment would work for people who got it in primary care (aPR: 1.16; 95% CI: 1.04–1.29) and those who got ART (aPR: 3.72; 95% CI: 1.20–11.55). Most patients had a successful treatment outcome, although it was below the target of 90%. Therefore, ensuring that such patients get monitoring in their treatment, especially in hospitals, and also get ART is important. It is crucial to strengthen and provide holistic support to ensure compliance and the success of TB and HIV treatment.

show abstract

Chromatographic-Based Platforms as New Avenues for Scientific Progress and Sustainability

2022

View full text Add to dashboard Cite

Chromatography was born approximately one century ago and has undergone outstanding technological improvements in innovation, research, and development since then that has made it fundamental to advances in knowledge at different levels, with a relevant impact on the well-being and health of individuals. Chromatography boosted a comprehensive and deeper understanding of the complexity and diversity of human–environment interactions and systems, how these interactions affect our life, and the several societal challenges we are currently facing, namely those related to the sustainability of our planet and the future generations. From the life sciences, which allowed us to identify endogenous metabolites relevant to disease mechanisms, to the OMICS field, nanotechnology, clinical and forensic analysis, drug discovery, environment, and “foodprint”, among others, the wide range of applications of today’s chromatographic techniques is impressive. This is fueled by a great variability of powerful chromatographic instruments currently available, with very high sensitivity, resolution, and identification capacity, that provide a strong basis for an analytical platform able to support the challenging demands of the postgenomic and post COVID-19 eras. Within this context, this review aims to address the great utility of chromatography in helping to cope with several societal-based challenges, such as the characterization of disease and/or physiological status, and the response to current agri-food industry challenges of food safety and sustainability, or the monitoring of environmental contamination. These are increasingly important challenges considering the climate changes, the tons of food waste produced every day, and the exponential growth of the human population. In this context, the principles governing the separation mechanisms in chromatography as well the different types and chromatographic techniques will be described. In addition, the major achievements and the most important technological advances will be also highlighted. Finally, a set of studies was selected in order to evince the importance of different chromatographic analyses to understand processes or create fundamental information in the response to current societal challenges.

show abstract

Plasma drug concentrations of 4-drug fixed-dose combination regimen and its efficacy for treatment of pulmonary tuberculosis under National Tuberculosis Elimination Programme: A prospective pilot study

Cited by 3 publications

References 22 publications

Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data

Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data

Factors Associated with Successful Drug Susceptible Tuberculosis Treatment among Tuberculosis – Human Immunodeficiency Virus Patients in DKI Jakarta Province 2020 – 2022

Chromatographic-Based Platforms as New Avenues for Scientific Progress and Sustainability

Contact Info

Product

Resources

About